Belite Bio, Inc (BLTE): Total Assets
$780.56M
As of 2025-12-31
+160.3%
3-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $780.56M | +413.1% | 2026-03-31, Balance as of period end |
| 2024-12-31 | $152.13M | +60.7% | 2026-03-31, Balance as of period end |
| 2023-12-31 | $94.64M | +113.8% | 2025-03-17, Balance as of period end |
| 2022-12-31 | $44.27M | +141.3% | 2024-03-12, Balance as of period end |
| 2021-12-31 | $18.35M | n/a | 2023-03-31, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Belite Bio, Inc (BLTE) | 2025-12-31 | $780.56M | +413.1% |
| Spyre Therapeutics, Inc. (SYRE) | 2025-12-31 | $777.78M | +27.8% |
| Maravai Lifesciences Holdings, Inc. (MRVI) | 2025-12-31 | $770.58M | -23.6% |
| NewAmsterdam Pharma Co N.V. (NAMS) | 2025-12-31 | $769.28M | -11.0% |
| MannKind Corp (MNKD) | 2025-12-31 | $792.18M | +101.1% |
| Cryoport, Inc. (CYRX) | 2025-12-31 | $764.99M | +8.7% |
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $763.63M | +31.5% |
| Disc Medicine, Inc. (IRON) | 2025-12-31 | $806.88M | +62.4% |
| Ocular Therapeutix, Inc (OCUL) | 2025-12-31 | $808.06M | +76.5% |
Compare BLTE, SYRE, MRVI, NAMS side by side · Screen every company in Pharmaceutical Preparations ↗